COVID-19 Clinical Trial
Official title:
A Phase II/III, Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy of RUTI® to Reduce the Severity of SARS-CoV-2 Infection
Verified date | February 2023 |
Source | PT. Innovative Pharma Solutions |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this study is to assess the efficacy of the RUTI® vaccine in achieving clinical improvement of COVID-19 symptoms and to evaluate the safety of RUTI® in patients with SARS-CoV-2 infection. The study will include a comparison between placebo and RUTI® vaccine in a 1:1 design.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | April 2022 |
Est. primary completion date | February 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Sign the Informed Consent before initiating the selection procedures. 2. Patients infected with SARS-CoV-2 (PCR +) with mild symptoms up to 7 days that do not require hospitalization, from the onset of symptoms. Mild symptoms, defined as the following criteria: cough, headache, fever (>37.5ºC), muscular pain and shortness of breath. 3. People = 18 years. 4. Peripheral oxygen saturation (SpO2) more than 94% on room air, not requiring supplemental oxygen. 5. Availability to meet the requirements of the protocol. Exclusion Criteria: 1. Pregnancy or breastfeeding. 2. Suspected of active viral or bacterial infection other than SARS-CoV-2. 3. Participation in another interventional study with potentially conflicting medication within 30 days before screening. 4. Severely immunocompromised people (data gathered from preexisting medical records and history taking). This exclusion category includes: 1. Subjects with human immunodeficiency virus (HIV-1). 2. Neutropenic subjects with less than 500 neutrophils / mm3. 3. Subjects with solid organ transplantation. 4. Subjects with bone marrow transplantation. 5. Subjects undergoing chemotherapy. 6. Subjects with primary immunodeficiency. 7. Severe lymphopenia with less than 400 lymphocytes / mm3. 8. Treatment with any anti-cytokine therapy. 9. Oral treatment with steroids, defined as daily doses of 10 mg prednisone or equivalent for more than 3 months. 5. Malignancy, or active solid or non-solid lymphoma from the previous two years. 6. BCG vaccination in the last 10 years. 7. Chloroquine or hydroxychloroquine administration in the last two weeks 8. Soy allergy 9. Direct involvement in the design or execution of the MYCOVIND clinical trial. 10. Do not have a smartphone. 11. Detection by the investigator of lack of knowledge or willingness to participate and comply with all requirements of the protocol. 12. Any other findings that, at the discretion of the investigator, may compromise compliance with the protocol or that may influence significantly the interpretation or the results of the effects of probiotics. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
PT. Innovative Pharma Solutions | Archivel Farma S.L., RUTI Immunotherapeutics S.L. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reduction patient rate to category 0 according to the WHO Ordinal scale by Day 30 after the initiation of vaccination | Reduction patient rate to category 0 according to the WHO Ordinal scale by Day 30 after the initiation of vaccination | 1 month | |
Secondary | Fever | Number of days with fever (=38 ºC). | 1 month | |
Secondary | Incidence of acute respiratory symptoms | Number of acute respiratory symptoms (SpO2 < 95%) | 1 month | |
Secondary | Patient rate reduction C1 or lower (WHO scale) | Reduction patient rate to category 1 or lower according to the WHO Ordinal scale | 1 month | |
Secondary | Incidence of death by SARS-CoV | Accumulated Incidence of death by SARS-CoV | 1 month | |
Secondary | Incidence admission at Intensive Care Unit | Accumulated incidence admission at Intensive Care Unit (documented) | 1 month | |
Secondary | Days in Intensive Care Unit | Number of days in Intensive Care Unit (documented) | 1 month | |
Secondary | Incidence for mechanic ventilation due to SARS-CoV-2 infection | Accumulated incidence for mechanic ventilation due to SARS-CoV-2 infection (documented) | 1 month | |
Secondary | Days of mechanic ventilation due to SARS-CoV-2 infection | Number of days of mechanic ventilation due to SARS-CoV-2 infection | 1 month | |
Secondary | Days hospital admission due to SARS-CoV-2 infection | Number of days hospital admission due to SARS-CoV-2 infection | 1 month | |
Secondary | Incidence of Treatment-Emergent Adverse Events | Proportion of patients reporting Adverse events (AEs, including serious adverse events) | 1 month | |
Secondary | Levels of IgG SARS-CoV2 | Plasma SARS-CoV2 spike protein-specific IgG level | 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Active, not recruiting |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|